Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05687916 · ClinicalTrials.gov registry record · Phase 2
A Study of TAK-861 in Participants With Narcolepsy Type 2
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT05687916 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 71 participants.
The verdict
NCT05687916, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
The main aim is to evaluate the effect of TAK-861 on symptoms of narcolepsy, including excessive daytime sleepiness (EDS) as measured by sleep latency from the Maintenance of Wakefulness Test (MWT). The study will enroll approximately 60 participants and they will be randomly assigned to 3 groups (20 per group) to take one of two different doses of TAK-861 or a placebo. All the participants will receive the treatment for 8 weeks. Participants will be asked to complete some questionnaires during the study. This trial will be conducted in North America, Europe, and Asia Pacific.
Interventions
- DRUG Placebo
- DRUG TAK-861 2 mg
- DRUG TAK-861 2 mg and 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2023-12-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05687916
The ClinicalTrials.gov registry entry for NCT05687916 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05687916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05687916 about?
NCT05687916 is a clinical study titled "A Study of TAK-861 in Participants With Narcolepsy Type 2". The main aim is to evaluate the effect of TAK-861 on symptoms of narcolepsy, including excessive daytime sleepiness (EDS) as measured by sleep latency from the Maintenance of Wakefulness Test (MWT). The study will enroll approximately 60 participants and they will be randomly assigned to 3 groups (...
What is the current status of trial NCT05687916?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2023-01-09. Estimated completion is 2023-12-25.
What interventions are being tested in trial NCT05687916?
The interventions under investigation include: Placebo (DRUG), TAK-861 2 mg (DRUG), TAK-861 2 mg and 5 mg (DRUG).
Who is sponsoring clinical trial NCT05687916?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.